Zensun Licenses China Marketing Rights For Heart Drug To SciClone
This article was originally published in PharmAsia News
Executive Summary
Zensun Science & Technology and SciClone Pharmaceuticals have signed an agreement that would have the U.S. drug maker license to market Neucardin, the first of a new class of drugs for treating advanced chronic heart failure.